Assessment and Treatment of Respiratory Disorders

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 629

Special Issue Editor

Special Issue Information

Dear Colleagues,

Respiratory problems are a great inconvenience to our society. Lifestyle has been modified in recent years, with a decrease in smoking, an increase in physical activity levels, better nutrition, among others. The respiratory system of the human body is made up of a set of elements that work in a coordinated manner in order to perform a vital function of the human being: breathing. At the socio-healthcare level, respiratory problems are one of the main causes of work absenteeism and health economic expenditure, as well as one of the main problems that causes a worsening of people's quality of life. We need high-quality research that addresses new clinical trends regarding the treatment (both pharmacological and non-pharmacological) and the evaluation of patients with respiratory disorders.

This Special Issue aims to encourage researchers in this field to submit their research papers and review papers addressing the evaluation and treatment of various respiratory pathologies (COPD, asthma, persistent COVID, respiratory failure, lung cancer, cystic fibrosis, etc.).

Dr. Ferran Cuenca-Martínez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mechanism
  • therapy
  • drugs
  • lung cancer
  • cystic fibrosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 2657 KiB  
Article
Identifying Molecular Pathophysiology and Potential Therapeutic Options in Iatrogenic Tracheal Stenosis
by Russell Seth Martins, Joanna Weber, Bryan Johnson, Jeffrey Luo, Kostantinos Poulikidis, Mohammed Jawad Latif, Syed Shahzad Razi, Al Haitham Al Shetawi, Robert S. Lebovics and Faiz Y. Bhora
Biomedicines 2024, 12(6), 1323; https://doi.org/10.3390/biomedicines12061323 - 14 Jun 2024
Viewed by 448
Abstract
Introduction: While most patients with iatrogenic tracheal stenosis (ITS) respond to endoscopic ablative procedures, approximately 15% experience a recalcitrant, recurring disease course that is resistant to conventional management. We aimed to explore genetic profiles of patients with recalcitrant ITS to understand underlying pathophysiology [...] Read more.
Introduction: While most patients with iatrogenic tracheal stenosis (ITS) respond to endoscopic ablative procedures, approximately 15% experience a recalcitrant, recurring disease course that is resistant to conventional management. We aimed to explore genetic profiles of patients with recalcitrant ITS to understand underlying pathophysiology and identify novel therapeutic options. Methods: We collected 11 samples of granulation tissue from patients with ITS and performed RNA sequencing. We identified the top 10 most highly up- and down-regulated genes and cellular processes that these genes corresponded to. For the most highly dysregulated genes, we identified potential therapeutic options that favorably regulate their expression. Results: The dysregulations in gene expression corresponded to hyperkeratinization (upregulation of genes involved in keratin production and keratinocyte differentiation) and cellular proliferation (downregulation of cell cycle regulating and pro-apoptotic genes). Genes involved in retinoic acid (RA) metabolism and signaling were dysregulated in a pattern suggesting local cellular RA deficiency. Consequently, RA also emerged as the most promising potential therapeutic option for ITS, as it favorably regulated seven of the ten most highly dysregulated genes. Conclusion: This is the first study to characterize the role of hyperkeratinization and dysregulations in RA metabolism and signaling in the disease pathophysiology. Given the ability of RA to favorably regulate key genes involved in ITS, future studies must explore its efficacy as a potential therapeutic option for patients with recalcitrant ITS. Full article
(This article belongs to the Special Issue Assessment and Treatment of Respiratory Disorders)
Show Figures

Figure 1

Back to TopTop